Long fasting is effective in inhibiting physiological myocardial 18F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis

EJNMMI Research

Volumn 4, Issue 1, 2014, Pages 1-11

  Morooka, Miyako ^a   Moroi, Masao ^a,b   Uno, Kimiichi ^c   Ito, Kimiteru ^a   Wu, Jin ^c   Nakagawa, Takashi ^a   Kubota, Kazuo ^a   Minamimoto, Ryogo ^a   Miyata, Yoko ^a   Okasaki, Momoko ^a   Okazaki, Osamu ^a   Yamada, Yoshihito ^d   Yamaguchi, Tetsuo ^d   Hiroe, Michiaki ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

^c Gaienhigashi Clinic   (Japan)

^d JR Tokyo General Hospital   (Japan)

Author keywords

Glucose utilization; Heparin loading; Inflammatory cells; Myocardial cells; Test preparation

Indexed keywords

EID: 84892511748     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-4-1     Document Type: Article

References (25)

1. Soejima K, Yada H: The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: with emphasis on the associated heart rhythm abnormalities. J Cardiovasc Electrophysiol 2009, 20:578-583.
2. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee: Statement on sarcoidosis. Am J Respir Crit Care Med 1999, 160:736-755.
3. Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, Gulenchyn KY, Dekemp RA, Dasilva J, Birnie D, Wells GA, Beanlands RS: The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012, 53:241-248.
4. Ishimaru S, Tsujino I, Takei T, Tsukamoto E, Sakaue S, Kamigaki M, Ito N, Ohira H, Ikeda D, Tamaki N, Nishimura M: Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Euro Heart J 2005, 26:1538-1543.
5. Ohira H, Tsujino I, Ishimaru S, Oyama N, Takei T, Tsukamoto E, Miura M, Sakaue S, Tamaki N, Nishimura M: Myocardial imaging with 18F-FDG PET and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 2008, 35:933-941.
6. Inglese E, Leva L, Matheoud R, Sacchetti G, Secco C, Gandolfo P, Brambilla M, Sambuceti G: Spatial and temporal heterogeneity of regional myocardial uptake in patients without heart disease under fasting conditions on repeated whole body 18F-FDG PET/CT. J Nucl Med 2007, 48:1662-1669.
7. Gropler RJ, Siegel BA, Lee KJ, Moerlein SM, Perry DJ, Bergmann SR, Geltman EM: Nonuniformity in myocardial accumulation of fluorine-18- fulorodeoxyglucose in normal fasted humans. J Nucl Med 1990, 31:1749-1756.
8. Tamaki N, Yonekura Y, Kawamoto M, Magata Y, Sasayama S, Takahashi N, Nohara R, Kambara H, Kawai C, Konishi J: Simple quantification of regional myocardial uptake of fluorine-18-deoxyglucose in the fasting condition. J Nucl Med 1991, 32:2152-2157.
9. Persson E: Lipoprotein lipase, hepatic lipase and plasma lipolytic activity effects of heparin and low molecular weight heparin fragment (Fragmin). Acta Med Scand Suppl 1988, 724:1-56.
10. Minamimoto R, Morooka M, Kubota K, Ito K, Masuda-Miyata Y, Mitsumoto T, Hirai R, Okazaki O, Hiroe M: Value of FDG-PET/CT using unfractionated heparin for managing primary cardiac lymphoma and several key findings. J Nucl Cardiol 2011, 18(3):516-520.
11. Langah R, Spicer K, Gebregziabher M, Gardon L: Effectiveness of prolonged fasting 18F-FDG PET/CT in the detection of cardiac sarcoidosis. J Nucl Cardiol 2009, 16:801-810.
12. Yamagishi H, Shirai N, Takagi M, Hoshiyama M, Akioka K, Takeuchi K, Yoshikawa J: Identification of cardiac sarcoidosis with 13 N-NH3/18 F-FDG PET. J Nucl Med 2003, 44:1030-1036.
13. Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N, Endo K, Yokoyama T, Suzuki T, Kurabayashi M: Usefulness of fasting 18 F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004, 45:1989-1998.
14. Lum DP, Wandell S, Ko J, Coel MN: Reduction of myocardial 2-deoxy-2-[18 F] fluoro-D-glucose uptake artifacts in positron emission tomography using dietary carbohydrate restriction. Mol Imaging Biol 2002, 4(3):232-237.
15. Wykrzkowska J, Lehman S, Williams G, Parker JA, Palmer M, Varkey S, Kolodny G, Laham R: Imaging of inflamed and vulnerable plaque in coronary arteries with 18 F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med 2009, 50:563-568.
16. Youssef G, Beanlands RS, Birnie DH, Nery PB: Cardiac sarcoidosis: applications of imaging in diagnosis and directing treatment. Heart 2011, 97:2078-2087.
17. Salvarani C, Pipitone N, Versari A, Vaglio A, Serafini D, Bajocchi G, Salvo D, Buzio C, Greco P, Boiardi L: Positron emission tomography (PET): evaluation of chronic periaortitis. Arthritis Rheum 2005, 53:298-303.
18. Sl B, Bax JJ, Case J, Delbeke D, Kurdziel KA, Martin WH, Patterson RE: PET myocardial glucose metabolism and perfusion imaging: part I- guidelines for patient preparation and data acquisition. J Nucl Cardiol 2003, 10:543-554.
19. Bax JJ, Wijns W, Cornel JH, Visser FC, Boersma E, Fioretti PM: Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: comparison of pooled data. J Am Coll Cardio 1997, 30:1451-1460.
20. Underwood SR, Bax JJ, vom Dahl J, Henein MY, Knuuti J, van Rossum AC, Schwarz ER, Vanoverschelde JL, van der Wall EE, Wijns W, Study Group of the European Society of Cardiology: Imaging techniques for the assessment of myocardial hidcernation: report of a Study Group of the European Society of Cardiology. Eur Heart J 2004, 25:815-836.
21. Boden G: Free fatty acids and insulin secretion in humans. Curr Diab Rep 2005, 5(3):167-170.
22. Boden G: Effects of free fatty acids (FFA) on glucose metabolism:significance for insulin resistance and type 2 diabetes. Exp Clin Endocrinol Diabetes 2003, 111(3):121-124.
23. Vettor R, Lombardi AM, Fabris R, Serra R, Pagano C, Macor C, Federspil G: Substrate competition and insulin action in animal models. Int J Obes Relat Metab Disord 2000, 24(2):S22-S24.
24. Cheng VY, Slomka PJ, Ahlen M, Thomson LE, Waxman AD, Berman DS: Impact of carbohydrate restriction with and without fatty acid loading on myocardial 18 F-FDG uptake during PET: a randomized controlled trial. J Nucl Cardiol 2010, 17(2):286-291.
25. Kaneta T, Hakamatsuka T, Takanami K, Yamada T, Takase K, Sato A, Higano S, Kinomura S, Fukuda H, Takahashi S, Yamada S: Evaluation of the relationship between physiological FDG uptake in the heart and age, blood glucose level, fasting period, and hospitalization. Ann Nucl Med 2006, 20(3):203-208.